About OnSemaglutide.com
OnSemaglutide.com is an independent informational resource for people using or considering GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound). We are not affiliated with Novo Nordisk, Eli Lilly, or any pharmaceutical company.
Our Editorial Standards
Every factual claim on this site is supported by a citation from a peer-reviewed journal, FDA prescribing information, or a published clinical trial. We cite the actual percentage from the actual trial — not rounded estimates or unsourced claims.
When the science is uncertain or mixed, we say so. We do not overstate findings or manufacture confidence.
Our medical disclaimer and affiliate disclosure appear on every article. We operate under FTC, GDPR, CCPA, and CAN-SPAM compliance requirements.
Key Sources We Use
- PubMed / NCBI (pubmed.ncbi.nlm.nih.gov)
- FDA drug prescribing information and approval history
- New England Journal of Medicine, The Lancet, JAMA
- STEP clinical trial series (Novo Nordisk / semaglutide)
- SURMOUNT clinical trial series (Eli Lilly / tirzepatide)
- OASIS clinical trial series (oral semaglutide)
Media Inquiries
For media inquiries, content partnerships, or corrections, contact us at: hello@onsemaglutide.com
Report an Error
We take accuracy seriously. If you find a factual error, please email us with the article URL and the correction. We review and update within 48 hours.